Market Closed -
OTC Markets
11:57:45 26/04/2024 pm IST
|
5-day change
|
1st Jan Change
|
0.005
USD
|
+150.00%
|
|
+150.00%
|
-85.71%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
573.8
|
156.8
|
132.4
|
165.1
|
18.07
|
Enterprise Value (EV)
1 |
435.1
|
114.5
|
128.2
|
137
|
12.67
|
P/E ratio
|
-6.68
x
|
-1.44
x
|
-1.3
x
|
-2.61
x
|
-0.45
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
38,251
x
|
-
|
-
|
-
|
0.92
x
|
EV / Revenue
|
29,009
x
|
-
|
-
|
-
|
0.65
x
|
EV / EBITDA
|
-5.65
x
|
-1.07
x
|
-1.61
x
|
-2.52
x
|
-0.81
x
|
EV / FCF
|
-12.1
x
|
-2.01
x
|
-3.02
x
|
-16.2
x
|
-0.47
x
|
FCF Yield
|
-8.27%
|
-49.8%
|
-33.2%
|
-6.18%
|
-211%
|
Price to Book
|
3.77
x
|
3.25
x
|
14.9
x
|
5
x
|
1.83
x
|
Nbr of stocks (in thousands)
|
44,946
|
43,799
|
61,161
|
81,580
|
1,25,075
|
Reference price
2 |
12.77
|
3.580
|
2.165
|
2.024
|
0.1444
|
Announcement Date
|
05/03/19
|
05/03/20
|
05/03/21
|
10/03/22
|
31/03/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
0.016
|
0.015
|
-
|
-
|
-
|
19.64
|
EBITDA
1 |
-67.39
|
-77.04
|
-107
|
-79.6
|
-54.28
|
-15.66
|
EBIT
1 |
-67.46
|
-77.15
|
-107.1
|
-79.7
|
-54.51
|
-15.68
|
Operating Margin
|
-4,21,650%
|
-5,14,360%
|
-
|
-
|
-
|
-79.83%
|
Earnings before Tax (EBT)
1 |
-66.88
|
-76.76
|
-108.7
|
-82.93
|
-58.16
|
-29.87
|
Net income
1 |
-66.93
|
-76.72
|
-108.8
|
-82.97
|
-58.38
|
-29.88
|
Net margin
|
-4,18,287.5%
|
-5,11,440%
|
-
|
-
|
-
|
-152.16%
|
EPS
2 |
-2.250
|
-1.910
|
-2.491
|
-1.670
|
-0.7754
|
-0.3245
|
Free Cash Flow
1 |
-34.73
|
-35.98
|
-56.98
|
-42.51
|
-8.464
|
-26.75
|
FCF margin
|
-2,17,035.16%
|
-2,39,841.67%
|
-
|
-
|
-
|
-136.23%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/03/18
|
05/03/19
|
05/03/20
|
05/03/21
|
10/03/22
|
31/03/23
|
Fiscal Period: December |
2021 Q1
|
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
---|
Net sales
1 |
0.006
|
0.004
|
20.1
|
0.005
|
2.237
|
2.612
|
3.712
|
EBITDA
|
-19.52
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-19.7
|
-18.37
|
1.532
|
-17.98
|
-10.6
|
-31.41
|
-0.629
|
Operating Margin
|
-3,28,350%
|
-4,59,225%
|
7.62%
|
-3,59,520%
|
-474.03%
|
-1,202.53%
|
-16.95%
|
Earnings before Tax (EBT)
1 |
-19.98
|
-19.11
|
0.838
|
-19.91
|
-11.75
|
-32.74
|
-12.11
|
Net income
1 |
-20
|
-19.14
|
0.819
|
-20.05
|
-11.8
|
-32.8
|
-12.06
|
Net margin
|
-3,33,400%
|
-4,78,600%
|
4.08%
|
-4,00,960%
|
-527.54%
|
-1,255.67%
|
-324.81%
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
06/05/21
|
05/08/21
|
04/11/21
|
10/03/22
|
17/05/22
|
17/08/22
|
01/12/22
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
111
|
139
|
42.3
|
4.24
|
28.1
|
5.4
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-34.7
|
-36
|
-57
|
-42.5
|
-8.46
|
-26.8
|
ROE (net income / shareholders' equity)
|
-84.3%
|
-56.9%
|
-111%
|
-290%
|
-287%
|
-279%
|
ROA (Net income/ Total Assets)
|
-46.7%
|
-31.9%
|
-49.3%
|
-58.8%
|
-44.1%
|
-24.2%
|
Assets
1 |
143.5
|
240.8
|
220.5
|
141.1
|
132.3
|
123.6
|
Book Value Per Share
2 |
3.370
|
3.380
|
1.100
|
0.1500
|
0.4000
|
0.0800
|
Cash Flow per Share
2 |
3.050
|
3.190
|
1.560
|
0.5400
|
0.6800
|
0.0800
|
Capex
1 |
0.19
|
0.19
|
0.05
|
0.01
|
0.01
|
-
|
Capex / Sales
|
1,181.25%
|
1,253.33%
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/03/18
|
05/03/19
|
05/03/20
|
05/03/21
|
10/03/22
|
31/03/23
|
|
1st Jan change
|
Capi.
|
---|
| -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|